We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

134 hedge funds and large institutions have $651M invested in Array Biopharma Inc in 2013 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 43 increasing their positions, 41 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

53% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 15

45% more capital invested

Capital invested by funds: $447M → $651M (+$203M)

5% more funds holding

Funds holding: 128 → 134 (+6)

5% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 41

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

93% less call options, than puts

Call options by funds: $79K | Put options by funds: $1.08M

Holders
134
Holders Change
+6
Holders Change %
+4.69%
% of All Funds
4.35%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
23
Increased
43
Reduced
41
Closed
15
Calls
$79K
Puts
$1.08M
Net Calls
-$997K
Net Calls Change
-$584K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$15.1M
2
PA
Pinnacle Associates
New York
+$13.8M
3
BA
BlackRock Advisors
Delaware
+$11.4M
4
TCM
TimesSquare Capital Management
New York
+$8.7M
5
State Street
State Street
Massachusetts
+$7.34M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$8.39M
2
BIT
BlackRock Institutional Trust
California
-$8M
3
RG
Redmile Group
California
-$6.53M
4
KIA
Kopp Investment Advisors
Minnesota
-$4.63M
5
CIP
Chartwell Investment Partners
Pennsylvania
-$4.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
WIL
126
Winifred I. Li
$19K +$18.4K +3,090 New
SFPIA
127
Stevens First Principles Investment Advisors
California
$12K -$8.91K -1,500 -43%
Envestnet Asset Management
128
Envestnet Asset Management
Illinois
$11K +$10.2K +1,711 New
AWMS
129
Advocacy Wealth Management Services
Georgia
$6K +$5.94K +1,000 New
Creative Planning
130
Creative Planning
Kansas
$5K – – –
PFPT
131
Pinnacle Financial Partners (Tennessee)
Tennessee
$3K +$2.44K +410 New
Dimensional Fund Advisors
132
Dimensional Fund Advisors
Texas
$2K – – –
PFG
133
Piershale Financial Group
Illinois
$1K – – –
Manulife (Manufacturers Life Insurance)
134
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$536 – – –
SGAM
135
Smith Group Asset Management
Texas
– -$1.38M -304,657 Closed
UOC
136
UBS O'Connor
Illinois
– -$908K -200,000 Closed
CCMH
137
Cornerstone Capital Management Holdings
New York
– -$709K -155,948 Closed
Jacobs Levy Equity Management
138
Jacobs Levy Equity Management
New Jersey
– -$664K -146,199 Closed
JG
139
Jefferies Group
New York
– -$456K -100,387 Closed
HCM
140
Highbridge Capital Management
New York
– -$354K -77,864 Closed
SIP
141
Stoneridge Investment Partners
Pennsylvania
– -$234K -51,452 Closed
Westfield Capital Management
142
Westfield Capital Management
Massachusetts
– -$195K -43,000 Closed
CA
143
Commerzbank Aktiengesellschaft
Germany
– -$108K -23,887 Closed
MA
144
MUFG Americas
New York
– -$90K -19,800 Closed
SCM
145
Stevens Capital Management
Pennsylvania
– -$58K -12,867 Closed
WAM
146
World Asset Management
Michigan
– -$49K -10,709 Closed
SBCM
147
Silver Bridge Capital Management
Massachusetts
– -$45K -10,000 Closed
HMS
148
Hanseatic Management Services
New Mexico
– -$22K -4,837 Closed
GC
149
Globeflex Capital
California
– -$1K -267 Closed
2 3 4 5
6

ARRY Hedge Fund Activity: Q3 2013 in Review

134 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2013, worth a combined $651M — up 45% from $447M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new ARRY positions and 15 closed out — a net gain of 8 holders — while 43 added to existing stakes and 41 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $15.1M. The largest seller was BVF Inc, cutting an estimated $8.39M.

  • 134 institutional investors held Array Biopharma Inc (ARRY) as of Q3 2013, up from 128 in Q2 2013.
  • Funds reported $651M of Array Biopharma Inc stock for Q3 2013, up 45% quarter-over-quarter.
  • 23 funds opened new Array Biopharma Inc positions in Q3 2013 and 15 closed out, a net change of +8 holders.
  • The largest Array Biopharma Inc buyer in Q3 2013 was T. Rowe Price Associates, an estimated $15.1M added.
  • The largest Array Biopharma Inc seller in Q3 2013 was BVF Inc, an estimated $8.39M sold.

Based on aggregated 13F filings for Q3 2013.